JOHNSON DAVID LEE 4
4 · Vera Therapeutics, Inc. · Filed Feb 6, 2026
Research Summary
AI-generated summary of this filing
Vera Therapeutics (VERA) COO David L. Johnson Receives Award
What Happened David L. Johnson, Chief Operating Officer of Vera Therapeutics (VERA), received equity awards on February 4, 2026 totaling 60,000 share-equivalents. The filing shows 20,000 shares acquired (A) at $0.00 and an additional 40,000 listed as a derivative award at $0.00 — total reported value $0 on grant. These awards are equity compensation grants (not open-market purchases or sales).
Key Details
- Transaction date: February 4, 2026; Form 4 filed February 6, 2026 (timely filing).
- Grants reported: 20,000 shares @ $0.00 (direct) and 40,000 derivative shares @ $0.00; combined = 60,000 RSU-type awards.
- Vesting (per footnote F1): One-fourth of the RSUs vests on each of Feb 20, 2027, 2028, 2029 and 2030, subject to continuous service.
- Prior holdings (per footnote F2): includes 643 shares acquired Mar 13, 2025 and 763 shares acquired Sept 12, 2025 under the company ESPP.
- Additional equity detail (per footnote F3): a separate stock option grant vests 1/48th beginning Mar 4, 2026 and monthly thereafter (this is a different award, not the Feb 4 RSU grant).
- Shares owned after transaction: not specified in the supplied details of this summary.
Context
- These are grant awards (A) — typical executive compensation intended to retain employees; they do not represent a purchase (bullish) or sale (liquidation) signal by themselves.
- The 40,000 amount is reported as a derivative (RSU-style) award; no cash changed hands at grant and shares are subject to future vesting conditions.
- For retail investors, grants can dilute existing shares over time as they vest but do not indicate immediate insider buying or selling activity.
Insider Transaction Report
Form 4
JOHNSON DAVID LEE
Chief Operating Officer
Transactions
- Award
Class A Common Stock
[F1][F2]2026-02-04+20,000→ 48,306 total - Award
Stock Option (right to buy)
[F3]2026-02-04+40,000→ 40,000 totalExercise: $42.74Exp: 2036-02-03→ Class A Common Stock (40,000 underlying)
Footnotes (3)
- [F1]Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.
- [F2]Includes 643 shares of Class A Common Stock acquired on March 13, 2025 and 763 shares of Class A Common Stock acquired on September 12, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.
- [F3]1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.
Signature
/s/ Joseph R. Young, Attorney-in-Fact|2026-02-06